Outputs (2)

Pricing strategies, executive committee power and negotiation leverage in New Zealand’s containment of public spending on pharmaceuticals (2022)
Journal Article
Main, B., Csanadi, M., & Ozieranski, P. (2022). Pricing strategies, executive committee power and negotiation leverage in New Zealand’s containment of public spending on pharmaceuticals. Health Economics, Policy and Law, 17(3), 348-365. https://doi.org/10.1017/s1744133122000068

This paper explores policy mechanisms behind New Zealand’s remarkable track record of cost containment in public pharmaceutical spending, contrasting with most other advanced economies. We drew on a review of official policy documents and 28 semi-str... Read More about Pricing strategies, executive committee power and negotiation leverage in New Zealand’s containment of public spending on pharmaceuticals.

Divergent spender: State‐societal and meso‐organisational mechanisms in the containment of public spending on pharmaceuticals in a liberal capitalist democracy (2021)
Journal Article
Main, B., & Ozieranski, P. (2021). Divergent spender: State‐societal and meso‐organisational mechanisms in the containment of public spending on pharmaceuticals in a liberal capitalist democracy. Sociology of Health & Illness, 43(6), 1518 - 1539. https://doi.org/10.1111/1467-9566.13343

For two decades, New Zealand has been placed consistently at the foot of OECD rankings for state expenditure on pharmaceuticals. In this article, we explore New Zealand's containment of pharmaceutical spending as a ‘divergent’ case of pharmaceutical... Read More about Divergent spender: State‐societal and meso‐organisational mechanisms in the containment of public spending on pharmaceuticals in a liberal capitalist democracy.